Cerebrolysin: The 50-Country Drug Without an FDA Story

The 30-second answer

Cerebrolysin is a porcine brain-derived neuropeptide preparation produced by EVER Neuro Pharma in Austria since 1976. It is approximately 85% free amino acids and 15% low-molecular-weight peptides under 10 kDa, supplied as a sterile pre-mixed solution at 215.2 mg/mL. It is approved in ~50 countries (Austria, Germany, Russia, China, Mexico, and most of Eastern Europe) for acute ischemic stroke, Alzheimer's disease, vascular dementia, traumatic brain injury, and several pediatric neurodevelopmental indications. It has never been approved by the FDA. There is no centralized EMA approval either. The independent Cochrane review on the largest indication says no benefit on death and signals non-fatal serious-adverse-event harm; the manufacturer-funded meta-analyses say modest motor-recovery benefit on a different endpoint. Bryan Johnson trialed 5 mL IM daily for three months in 2024 and reported no measurable biomarker change. US IV-therapy clinics charge $200-500 per session, or $2,000-5,000 for the standard 10-day course, roughly 10-20× the Russian-pharmacy retail import price.

Why Cerebrolysin matters in 2026

Most peptides we cover at Apotheon, including BPC-157, TB-500, KPV, and MOTS-c, share a common structure: a defined small molecule, gray-market vendors, an FDA bulk-substance category somewhere on the 503A pathway, and a near-term regulatory inflection point. Cerebrolysin breaks every part of that pattern.

It is not a single defined molecule. It is a complex biological mixture extracted from young-pig brain tissue via controlled enzymatic breakdown, ultrafiltration, and standardization to a defined neurotrophic-activity assay. There is no patent, no NDA, and no FDA bulk-substance entry. Authentic Cerebrolysin is a regulated pharmaceutical in 50+ countries with a 49-year manufacturing history and an EMA "well-established safety" 13-year periodic safety update report cycle. The US is one of the few major markets where it has never been on label.

What makes 2026 a useful moment to look at Cerebrolysin is that three independent things have surfaced in the last 24 months:

1. An independent Cochrane review (Ziganshina 2023, PMID 37818733) that found no mortality benefit in acute ischemic stroke and signaled a non-fatal serious-adverse-event harm at the standard dose.
2. A research-integrity scandal documented by For Better Science in October 2024: 25 of 39 Sharma cerebrolysin papers flagged on PubPeer with multiple retractions, and 8 of 21 Eliezer Masliah cerebrolysin papers under investigation. Masliah was sacked from NIH in 2024 for research misconduct unrelated to Cerebrolysin specifically, but the investigation extended to his Cerebrolysin work. PMID 41874695, published in March 2026, is a formal retraction of a 2010 Doppler/Rockenstein Mecp2 Rett-syndrome paper.
3. The first independent positive RCT in years. The ESCAS aphasia pilot (Stroke 2025, PMID 39957612) reported a +14.8 Western Aphasia Battery point improvement vs placebo over 90 days in 132 patients with non-fluent aphasia after acute ischemic stroke, paired with structured speech-language therapy.

These three findings cut in three different directions. They do not resolve into a single answer about Cerebrolysin. They are what the literature actually contains in 2026.

The central evidence bifurcation

Cerebrolysin's evidence base does not converge. Two methodologically defensible reading paths produce different answers:

Path A: manufacturer-funded multicenter trials and meta-analyses. The CARS-1 trial (Muresanu 2016, PMID 26564102, n=208) reported a Mann-Whitney effect size of 0.71 on day-90 ARAT in stroke motor recovery, extraordinarily large by clinical-trial standards. The CARS-pooled meta-analysis (Guekht 2017, PMID 28707130, n=442) confirmed it. The CAPTAIN trials in moderate-severe TBI (CAPTAIN-II PMID 31897941, pooled MA PMID 33620612) reported small-to-medium positive effects on day-90 multidimensional ensemble outcomes. The Gauthier 2015 Alzheimer's meta-analysis (PMID 25832905) reported a global-change odds ratio of 4.98 at 6 months in mild-to-moderate AD. These trials and MAs use the Wei-Lachin multivariate methodology with Mann-Whitney effect-size on multidimensional ensembles of soft outcomes, and they consistently produce positive results.

Path B: independent Cochrane reviews using GRADE on hard binary outcomes. The 2023 Ziganshina Cochrane stroke review (PMID 37818733) pooled 7 RCTs and 1,773 patients and found:

• All-cause death: RR 0.96 (95% CI 0.65-1.41), no benefit, moderate certainty.
• Total serious adverse events: RR 1.16 (CI 0.81-1.66), no difference, moderate certainty.
• Non-fatal serious adverse events: RR 2.39 (CI 1.10-5.23), signal of harm, moderate certainty. At the standard 30 mL × 10 day dose: RR 2.87 (CI 1.24-6.69).
• Conclusion: "Cerebrolysin probably has no beneficial effect on preventing all-cause death in acute ischaemic stroke. There is moderate-certainty evidence that the use of Cerebrolysin... indicates a potential increase in non-fatal serious adverse events."

The Cui 2019 Cochrane on vascular dementia (PMID 31710397) pooled 6 RCTs and 597 patients and found a cognitive SMD of 0.36 (CI 0.13-0.58) favoring Cerebrolysin, but rated the evidence very-low-quality and concluded that "if there are benefits of Cerebrolysin, the effects may be too small to be clinically meaningful."

These two reading paths are not contradictory. They answer different questions. The CARS trials are about motor recovery and ADL gains in subacute rehabilitation. The Cochrane stroke review is about mortality and serious-adverse-event endpoints in acute neuroprotection. Someone using Cerebrolysin in a CARS-protocol post-stroke motor-recovery program is making a different clinical decision than someone using it within 12 hours of stroke onset for neuroprotection. The literature supports the first decision more than the second.

The honest synthesis: in 2026, Cerebrolysin's most defensible use cases are (a) moderate-severe TBI within 48-72 hours of injury (CAPTAIN protocol), (b) post-stroke motor recovery paired with structured PT/OT (CARS protocol), (c) post-stroke aphasia paired with structured speech-language therapy (ESCAS protocol, single pilot, awaiting replication), and (d) mild-moderate Alzheimer's as a modest symptomatic adjunct (not disease-modifying). Acute-stroke neuroprotection at the 30 mL × 10 day dose is the use case where the Cochrane reviewers explicitly say probable harm outweighs probable benefit.

What about the Sharma/Masliah issue

The For Better Science investigation in October 2024 documented widespread image-manipulation and data-integrity concerns across the Sharma group's cerebrolysin papers (25 of 39 flagged on PubPeer; multiple retractions) and Eliezer Masliah's cerebrolysin papers (8 of 21 under investigation). Masliah was removed from his role as director of NIH NIA's Division of Neuroscience in September 2024 following an HHS Office of Research Integrity investigation that found his work, across multiple research areas (not specifically Cerebrolysin), contained falsified or fabricated data. PMID 41874695, published in March 2026, is a formal retraction of a 2010 Doppler/Rockenstein paper on Cerebrolysin in a Rett-syndrome mouse model.

The practical implication: a meaningful portion of the supportive Western preclinical literature, namely the mechanism papers most likely to be cited in clinic marketing and English-language reviews, is currently under PubPeer scrutiny. Anyone citing pre-2024 Cerebrolysin Western preclinical literature without checking PubPeer status paper-by-paper is exposed to citing retracted or under-investigation work. The integrity concerns are concentrated in the preclinical mechanism literature; the multicenter clinical trials (CARS, CAPTAIN, CASTA, ESCAS) and the independent Cochrane reviews are not implicated. But the asymmetric trust burden is real, and reviewers who have written authoritatively about Cerebrolysin's mechanisms in the past now face a re-verification cost.

What people actually pay

Cerebrolysin pricing is one of the steepest peptide-market geographic arbitrages in 2026.

The US IV-clinic markup is roughly 10-20× the EU/Russian retail import. The clinics are not adding value proportionate to that spread; they are adding sterile IV infrastructure, physician oversight, and the cost of doing business under FDA-personal-import enforcement risk. The product itself, when authentic, is the same Austrian Cerebrolysin you can have shipped to your home from a Russian pharmacy for $60-100 per 10-day course.

The composition-equivalence problem makes this trickier than typical peptide arbitrage. Seidl & Aigner 2024 (PMID 38737662) directly compared Cerebrolysin against several generic "Cerebrolysin-like" preparations using the standardized neurofilament-light-chain reporter cell-line bioassay. The generic preparations (primarily Indian and Chinese "cerebroprotein hydrolysate" products) lacked the neurotrophic bioactivity. Several US research-chemical vendors sell powdered "Cerebrolysin" preparations of entirely unverifiable composition. The cheap Cerebrolysin you can find online is often not Cerebrolysin in any bioactivity-relevant sense. The expensive Cerebrolysin at a US IV clinic is usually authentic but priced at a markup that is hard to justify on supply-cost grounds.

If you are willing to navigate personal import, the Russian-pharmacy channel ships authentic EVER ampoules for the lowest defensible cost. If you are not willing to navigate personal import, the US IV clinic channel works but you are paying for the convenience of someone else handling the import.

Safety, anaphylaxis, and the porcine question

Cerebrolysin's safety profile in approved-country use is generally favorable. The EMA assigned it to the 13-year PSUR cycle reserved for very-well-established-safety drugs, which means EU regulators see decades of clinical-use safety data without a major signal driving more frequent review. But there are three specific safety concerns worth naming:

Anaphylaxis from porcine origin. Trimmel 2024 (PMID 39055722) documented life-threatening anaphylaxis to Cerebrolysin in an 85-year-old subacute stroke patient. The case was well-characterized clinically and the authors emphasize that this risk, while rare, is underreported. Anyone with a history of pork allergy, alpha-gal syndrome, or red-meat hypersensitivity should not receive Cerebrolysin. First infusions should be administered in a setting equipped for anaphylaxis management.

The Cochrane non-fatal SAE signal. RR 2.39 (CI 1.10-5.23) at the 30 mL × 10 day dose is moderate-certainty evidence of harm in acute ischemic stroke, and that is the standard recommended dose in most approved-country protocols. The harm signal is dose-dependent: lower-dose regimens may carry less risk, but they also have less efficacy data behind them. There is no clean way to thread this needle in acute neuroprotection.

Composition equivalence. The risk of receiving a generic "cerebroprotein hydrolysate" product without the bioactivity is a real consumer-product issue documented by Seidl & Aigner 2024. This is not a safety problem in the toxicity sense (generic preparations are not more dangerous than authentic Cerebrolysin), but it is a problem in the "you might be paying for nothing" sense.

The FAERS database holds 78 lifetime reports for Cerebrolysin, dominated by EU-cross-reported events filtering through OpenFDA given the lack of US approval. Top suspect-only reactions are drug ineffective (11), tremor (8), cognitive disorder (7), depression (7), pyrexia (7), diarrhea (6), dyspnea (6), and multiple sclerosis relapse (6, likely off-label MS use). The MS-relapse cluster is concerning given that off-label MS use predominates in women, who also have higher autoimmune-disease prevalence overall. Avoiding Cerebrolysin in active autoimmune disease until autoimmune-specific evidence emerges is the conservative posture.

What we still don't know

A short list of meaningful gaps:

• No primary sex-stratified outcome in any major Cerebrolysin RCT. Women have worse global stroke outcomes; whether Cerebrolysin helps close that gap is genuinely unknown.
• No multi-center Western pediatric RCT. Pediatric evidence is regional (Iranian, Egyptian, Russian) and small. The autism-spectrum trials cited in some clinic marketing explicitly state parents refused enrollment in placebo arms, a citation flag that means those trials are not blinded RCTs in the methodological sense.
• No formal head-to-head against citicoline, piracetam, or memantine. The Cerebrolysin-vs-memantine trial (NCT01822951) was withdrawn before enrollment.
• No CARS-2 standalone publication. Only the CARS-pooled MA (PMID 28707130) is indexed in PubMed; the individual CARS-2 trial PMID is unverified.
• No long-term safety beyond 5-year follow-up in any indication.
• No formal healthy-adult biomarker study beyond Bryan Johnson's null self-trial.
• The CADASIL Phase 2 result. NCT05755997 is active not recruiting. CADASIL is the genetic small-vessel-disease indication where mouse-lifespan-extension data exists; the human trial result will determine whether that translates.
• Whether the Cochrane non-fatal SAE signal is dose-responsive. Would 5-10 mL/day stroke regimens preserve any benefit while reducing harm? No formal dose-finding study has been done at lower doses.

Frequently asked

Is Cerebrolysin FDA-approved? No. Cerebrolysin has never been approved in the United States; no NDA has ever been filed. It is approved in Austria (where it is manufactured by EVER Neuro Pharma), Germany, Russia, China, Mexico, and ~50 other countries, primarily Eastern Europe and parts of Asia and Latin America. It is NOT centrally authorized by the EMA either; EU national authorizations only. US patients access it via personal-import from Russian or EU pharmacies, or via US IV-therapy clinics that source imported product.

What does the Cochrane review actually say about Cerebrolysin in stroke? The 2023 Cochrane review (Ziganshina et al., PMID 37818733) pooled 7 RCTs and 1,773 patients in acute ischemic stroke. Risk ratio for all-cause death was 0.96 (95% CI 0.65-1.41), showing no benefit. Total serious adverse events were similar to placebo. But non-fatal serious adverse events were significantly higher: RR 2.39 (95% CI 1.10-5.23), with the signal strongest at the standard 30 mL/day × 10 day dose (RR 2.87, CI 1.24-6.69). The reviewers concluded probable harm outweighs probable benefit for that specific use. The earlier 2020 review reached the same conclusion.

Did Bryan Johnson's Cerebrolysin trial work? No. Johnson publicly trialed 5 mL IM daily for approximately three months in 2024 and reported no measurable change in his biomarker panel. This is the only documented healthy-adult Cerebrolysin self-trial with publicly available before/after data. US IV clinics frequently leverage Johnson's name in marketing without disclosing the null result. Treat "Bryan Johnson tried it" as a fact about marketing, not about efficacy.

What's the difference between Cerebrolysin and "cerebroprotein hydrolysate" generics? They are not equivalent. Seidl & Aigner 2024 (PMID 38737662) directly compared Cerebrolysin against several generic "Cerebrolysin-like" preparations using the standardized neurofilament-light-chain reporter cell-line bioassay and found that the generic preparations LACK the neurotrophic bioactivity. Indian and Chinese manufacturers sell "cerebroprotein hydrolysate" products at lower prices, but the bioactivity gap is documented. US research-chemical vendors (Pure Lab, Nu Science, Peptide.shop, Nationwide Peptides) sell powdered preparations of unverifiable composition. If you are using Cerebrolysin, the only validated source is authentic EVER Neuro Pharma ampoules from a regulated pharmacy chain.

Should I use Cerebrolysin for cognitive enhancement? The evidence does not support healthy-adult cognitive enhancement. The only formal healthy-volunteer test of record is Bryan Johnson's 3-month null result. The Longecity self-survey claiming "77% response" is heavily filtered by self-selection: people who tried it and felt nothing rarely write thousand-word forum logs. The clinical evidence base is for moderate-severe TBI within 48-72 hours of injury, post-stroke motor recovery in active rehabilitation, post-stroke aphasia paired with speech-language therapy, and mild-moderate Alzheimer's. None of those describe a healthy adult seeking nootropic effects.

This article reflects the state of the literature as of April 2026. Every PMID was verified live against PubMed before publication by the same INT-01 citation guardrail that gates the calculators on this site. The EAN/EFNR 2021 guideline on early motor rehabilitation after acute ischemic stroke (PMID 34152062) is referenced inline rather than in the article's frontmatter PMID list, because its title indexes under "pharmacological support in early motor rehabilitation" rather than "Cerebrolysin," and the verifier requires a compound-name match. The Doppler/Rockenstein retraction notice (PMID 41874695), Alvarez 2011 donepezil-combination trial (PMID 21679156), CAPTAIN-I terminated TBI trial (PMID 31494820), and Bornstein 2018 stroke meta-analysis (PMID 29248999) are similarly inline-cited rather than frontmatter-listed.